Home > A. Molecular pathology > Targeted therapy > Small molecules > rociletinib
rociletinib
Saturday 15 October 2016
rociletinib (CO-1686)
Targeted therapy
NSCLC
- Resistance to the first (erlotinib , gefitinib )- and second (afatinib )-generation EGFR-TKIs provided the rationale behind the development of the third-generation inhibitors (rociletinib , osimertinib ).
Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients.
Open references
New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Van Der Steen N, et al. Onco Targets Ther. 2016. 27785053 Free
References
Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2015;33 (suppl; abstr 8001).
